The Role of Skeletal Radiology and the Limits of Serologic Assays in Distinguishing among the Causes of Inflammatory Arthritis

Bruce Rothschild*, Michael Gernert and Ottar Gadeholt

Department of Medicine, IU Health, Muncie, Indiana, USA
Department of Rheumatology, Medical Clinic II, University Clinic, Würzburg, Germany

*Corresponding author: Bruce Rothschild, Department of Medicine, IU Health, Muncie, Indiana, USA

Abstract

Radiologic findings are important for the diagnosis and treatment of inflammatory joint disease.

Current classification criteria utilize different serological findings, such as anti-citrullinated-peptide antibodies (ACPA) and rheumatoid factor (RF), as well as clinical findings, for diagnosis of rheumatoid arthritis (RA). The presence of erosions allows diagnosis, even if serological criteria are not fulfilled. However, the pertinent erosions are not clearly defined.

Previous studies have shown different patterns of radiographic changes in RA patients, possibly representing different mechanisms of damage. The association between different damage patterns and serological findings is not known.

This study explores the association between serological factors and radiographic findings in patients with a clinical diagnosis of RA, RF-/ACPA-positive and negative, and spondylarthropathy, from a single centre. Anonymized radiographs were evaluated blindly, assessing presence of osteopenia, marginal and subchondral erosions, peri-erosional sclerosis, joint surface crumbling, and joint fusion. Radiological diagnosis was then correlated with serological findings.

193 patients were studied (RA/spondylarthropathy 151/42). Age and disease duration did not differ significantly between the groups. Subchondral and wrist erosions were significantly more common in clinically-diagnosed RA patients. RF, but not ACPA, was associated with metacarpal-carpal and metatarsal-tarsal erosions. Generally, no serological or clinical parameter could reliably predict radiological changes in patients with peripheral arthritis, neither those findings associated with RA, nor those rather associated with spondylarthropathy.

This study suggests that serology alone is unable to predict the mode of radiological damage in patients with peripheral inflammatory joint disease. To prevent confounding, further studies into arthritis pathophysiology should therefore take both radiological and serological findings into account.

Keywords

Rheumatoid arthritis, Spondyloarthropathy, Rheumatoid factor, Citrullinated-peptide antibodies, Ankyloses, Joint erosion

Introduction

Radiologic findings play a central role in the diagnosis, treatment, and prognosis of inflammatory joint disease. The ACR/EULAR classification criteria, the most recent classification criteria for rheumatoid arthritis (RA), permits that the criteria may be bypassed if erosions are present [1]. For the current psoriatic arthritis (PsA) classification criteria, radiographic change is one of the five criteria, of which the patient must fulfill > 3 [1]. For PsA, radiographic findings are clearly defined, whereas the 2010 ACR/EULAR publication for diagnosis of RA does not define ‘erosive disease’ precisely.

Expansion of the diagnostic criteria for rheumatoid arthritis and deletion of exceptions increases sensitivity, but at the expense of specificity [2-5]. The result has been a tendency [6-8] to group all individuals with a predominantly non-axial inflammatory arthritis in this rheumatoid arthritis category [9]. Two decades later, modification of criteria included the caveat: “Absence
of an alternative diagnosis that better explains the synovitis", which, even if one assumes, that RA despite its heterogeneity is a single entity, puts great reliance on the diagnostic skills of the evaluating individual and their perspectives of disease. The major confounding factors appear to be spondyloarthropathy and calcium pyrophosphate deposition disease and occasionally, gout [10-12], which share some characteristics with rheumatoid arthritis. It is suggested that rheumatoid arthritis be recognized on the basis of marginally distributed, symmetrical polyarticular erosions, in the absence of axial (odontoid disease-excepted) involvement, to avoid failure to distinguish it from these different diseases [5,12-15]. Alternatively, subchondral erosions and peripheral joint fusion teleologically might be considered results of a process variant from those producing marginal erosions or in which periaricular (or peri-erosional) bone are lost.

Another approach to RA classification has been serologically-based. Historically, serology-based practitioners have used presence or absence of rheumatoid factor as defining whether an individual is suffering from rheumatoid arthritis [16]. However, rheumatoid factor is elevated in other connective tissue disorders, other forms of inflammatory arthritis, malignancy, chronic infections (e.g., endocarditis, rheumatic fever, tuberculosis, syphilis, viral disease, parasitic disease), rheumatic fever, pulmonary fibrosis, sarcoidosis and chronic renal disease), as well as among healthy elderly [17,18]. The tradeoff between sensitivity and specificity results in a titer cutoff that has a 5% false positive result. The former impression that presence of rheumatoid factor has specificity for diagnosis of a specific variety of inflammatory arthritis probably derives from lumping of all inflammatory arthritis as rheumatoid [19]. Adding anti-citrullinated peptide antibody status to such assessments produces additional perspectives [20], but specificity for specific clinical patterns or radiologic findings requires further analysis.

For RA, the enormous significance of erosive disease (allowing a definite RA diagnosis, independent of other findings), together with the poor definition of what actually constitutes erosive disease, means that further research into the discriminative ability of radiological damage is needed. Also, the link between serologic findings such as ACPA and RF, and radiological damage is tenuous, at best.

The problem is further compounded by the variability of RA itself, both concerning serology, therapeutic response [21,22] and long-term prognosis [23,24]. Several studies have shown differences between several “subtypes” of RA, both concerning joint distribution [25-27] and bone morphology [27]. The results, however, are not entirely consistent [28].

Several different modes of damage are attributed to RA [29], including erosions, periaricular osteopenia, ankylosis, periaricular ossification [30], and carpal dissolution [31]. It is not known whether these findings are specific for RA, and if they are dependent on other characteristics such as RF or ACPA status.

It is conceivable that different modes of damage are visible manifestations of specific pathophysiological processes, independent of serology. If that is the case, then further research could enable ‘targeted’ interventions, choosing a therapeutic agent suited to the patient’s form of disease.

This study aims to investigate the prevalence and discriminatory ability of different radiographic characteristics, concerning marginal or subchondral erosions, joint crumbling, MCC and MTT joint erosions or peripheral joint fusion.

**Methods**

The clinical data base (EMIL, itc-ms.de, Marburg, Germany) was utilized to identify individuals treated at the Würzburg University rheumatology clinic from with hand X-rays. The study was approved by the ethics department of the Würzburg University clinic. All X-ray images had been obtained for clinical indications. No additional radiographs were performed for this study. Patient pseudonymization was performed on-site, no sensitive data were transmitted during the study. Given the retrospective study design, anonymized X-rays and absence of transmission of sensitive data, written patient consent was not required.

Patients were initially divided on the basis of clinical diagnosis into two groups (spondyloarthropathy and RA), with the latter divided according to rheumatoid factor (RF) presence or absence (Table 1). The RF positive subset was further subdivided according to presence or absence of anti-cyclic citrullinated peptide (CCP) antibodies. As all CCP-positive individuals were also rheumatoid factor positive, there was no RF-negative/CCP-positive comparison group. Age and sex were recorded for each group. Clinical diagnosis was performed by trained rheumatologists in a regular context.

**Table 1:** Patient characteristics. Data given as mean (range), except where noted.

| Patient group | Total | RA (ACPA+/RF+) | RA (ACPA-/RF+) | RA (ACPA-/RF-) | SpA |
|---------------|-------|----------------|----------------|----------------|-----|
| n (M/W)       |       |                |                |                |     |
| 193 (60/133)  | 56 (18/38) | 39 (9/30) | 56 (17/39) | 42 (16/26) |
| Age           | 59 (28-86) | 61 (37-79) | 66 (32-86) | 62 (37-84) | 49 (26-70) |
| Disease Duration | 13 (0-54) | 14 (0-31) | 17 (1-54) | 10 (0-49) | 9 (0-31) |
Clinical diagnosis of RA was based on fulfilment of the 2010 ACR/EULAR criteria for RA [32]. Clinical diagnosis of spondyloarthropathy was based on the current classification criteria for psoriatic arthritis and axial spondyloarthritis [33].

Rheumatoid factor (RF) was determined by the RF-II test (Roche Diagnostics GmbH, Mannheim, Germany). CCP were determined by the ELISA CCP Well test (Phadias AB, Uppsala, Sweden). Tests were considered positive when above upper limit of normal (ULN) (16 IU/ml and 10 U/ml, respectively).

Anterior-posterior and oblique hand/wrist radiographs were anonymized for confidentiality. Radiographs were evaluated by a single blinded study group member (BMR), assessing general osteopenia and reactive new bone formation. Each joint individually for periarticular osteopenia, marginal and subchondral erosions, peri-erosional sclerosis, joint surface crumbling or accretion/calcification and joint fusion. The goal of this study was to assess the fundamental components of bone/joint assessment, rather than the individual joint extent as suggested by mathematical coding systems (e.g., Sharp/von der Heijde scoring system) [34].

Radiologic diagnoses were based on presence or absence of marginal or subchondral erosions, joint crumbling, metacarpal-carpal joint (MCC) and metatarsal-tarsal (MTT) joint erosions or peripheral joint fusion. The diagnosis of RA was based on the presence of polyarticular, marginally distributed erosions, axial skeleton (atlantoaxial junction excepted) sparing and absent joint fusion [5,35]. A diagnosis of spondyloarthropathy was based on the presence of axial joint disease, joint fusion, or peripheral, predominantly subchondral erosions and reactive new bone formation [10,35]. The diagnosis of calcium pyrophosphate deposition disease diagnosis was based on recognition of a calcified sheet (reflecting onto the articular surface), radiocarpal articular surface indentation, or calcific concretions at the joint surface margins [11,35]. The diagnosis of gout was based on recognition of sharply defined erosions with new bone formation producing a space-occupied appearance with overhanging edge [12,35]. Radiologic alterations in the four groups were compared to assess specificity of both serological and radiological findings.

Statistical analysis was performed by Chi square and Fisher exact tests to assess comparability of groups as to sex, age and disease duration, as well as the relationship of rheumatoid factor and CCP serology to presence of MCC/MTT joint involvement, subchondrally-distributed erosions, wrist-limited joint distribution of erosions, peripheral joint fusion, peripheral joint fusion and combinations thereof, as well as for the presence of arthritis mutilans.

**Results**

The study population (Caucasian) consisted of 60 males and 133 females (Table 1). There were 44 males and 107 females with RA; 16 males and 26 Females with spondyloarthropathy (Chi square = 1.2303, n.s.).

| Crumbling       | Fusion       |
|-----------------|-------------|
| **ACPA+/RF+**   | 10 (2/8)    |
| Age             | 60 (43-73)  |
| Disease duration| 15 (5-20)   |
| **ACPA-/RF+**   | 4 (1/3)     |
| Age             | 69 (62-74)  |
| Disease duration| 18 (14-24)  |
| **ACPA-/RF-**   | 9 (2/7)     |
| Age             | 73 (57-83)  |
| Disease duration| 8 (1-17)    |
| **SpA**         | 1 (0/1)     |
| Age             | 61          |
| Disease duration| 0           |
| **Total**       | 24 (5/19)   |
| Age             | 67 (43-83)  |
| Disease duration| 12 (0-24)   |

| Osteopenia       | Marginal Erosions |
|------------------|-------------------|
| **ACPA+/RF+**    | 25 (8/17)         |
| Age              | 67 (50-82)        |
| Disease duration | 16 (2-31)         |
| **ACPA-/RF+**    | 17 (1/15)         |
| Age              | 69 (32-87)        |
| Disease duration | 15 (3-32)         |
| **ACPA-/RF-**    | 15 (4/11)         |
| Age              | 70 (53-83)        |
| Disease duration | 10 (1-38)         |
| **SpA**          | 6 (3/3)           |
| Age              | 43 (25-59)        |
| Disease duration | 9 (0-27)          |
| **Total**        | 63 (17/46)        |
| Age              | 66 (25-87)        |
| Disease duration | 14 (0-49)         |

| Subchondral Erosions | Peri-erosional sclerosis |
|----------------------|--------------------------|
| **ACPA+/RF+**        | 7 (0/7)                  |
| Age                  | 61 (38-82)               |
| Disease duration     | 15 (4-31)                |
| **ACPA-/RF+**        | 4 (1/3)                  |
| Age                  | 59 (36-74)               |
| Disease duration     | 25 (18-32)               |
| **ACPA-/RF-**        | 3 (0/3)                  |
| Age                  | 60 (41-83)               |
| Disease duration     | 9 (4-17)                 |
| **SpA**              | 1 (0/1)                  |
| Age                  | 40                       |
| Disease duration     | 6                        |
| **Total**            | 15 (1/14)                |
| Age                  | 59 (36-83)               |
| Disease duration     | 16 (5-32)                |

Table 2: Patient characteristics for different radiological changes. Data given as mean and range.
The age average age for individuals diagnosed with RA was 64, ranging from 32 to 86, compared to 49, ranging from 26-70 for spondyloarthropathy (Table 2). Individuals diagnosed as having RA were not significantly older than those with spondyloarthropathy (t test = 0.8364, n.s.) nor had disease of longer duration (average 13 versus 9) (t test = 0.56744, n.s.).

Among individuals clinically diagnosed as having RA, 56 were positive for RF and CCP; 39 RF, only for RF; and 56, negative for both. Sex ratios were indistinguishable (Chi square = 0.9288, n.s.).

Statistical analysis (Table 3) revealed significantly less seropositivity among individuals with no radiologic signs of inflammation/erosive disease. Both rheumatoid factor and antibodies to CCP were present significantly more often among individuals with subchondral erosions or erosions limited to wrists. Sixteen of twenty individuals with erosive disease of wrists were positive for rheumatoid factor; nine, for CCP antibodies. Rheumatoid factor, but not antibodies to CCP, was present significantly more often in those with MCC/MTT erosions.

All individuals with subchondral erosions, joint fusion and MTT/MCC joint involvement were both rheumatoid factor and CCP antibody positive. Five of seven with just joint fusion and MCC/MTT involvement were positive for rheumatoid factor; thee for CCP antibodies.

Twelve of 32 individuals radiologically-diagnosed as having RA were positive for rheumatoid factor, 17 of whom were also positive for CCP antibodies. Forty-five of 63 individuals radiologically-diagnosed as having spondyloarthropathy were positive for rheumatoid factor; 24 of whom were also positive for CCP antibodies.

Two of four individuals radiologically diagnosed with gout were positive for rheumatoid factor, one of whom was also positive for CCP antibodies.

Discussion

In this study, we find no serological or clinical parameter that can reliably predict radiological changes in patients with peripheral arthritis. This does not only apply to changes typical for RA, such as marginal erosions and periarticular osteopenia, but also for lesions that are rather considered to be associated with peripheral spondyloarthritis, such as joint fusion and subchondral erosions.

Radiological findings suggestive of SpA were also found in ACPA positive, RF positive individuals and in those fulfilling the 2010 ACR/EULAR criteria.

While RF and CCP were more common among individuals with radiographs diagnostic for a specific arthritis than in those with normal X-rays (Table 3), the prevalence did not vary among them. Seropositivity in individuals with subchondral erosions, MCC/MTT localization of erosions or presence of peripheral joint fusion was indistinguishable among the groups, but significantly greater than those without such findings. Both RF and CCP were more common in individuals with subchondral erosions than in the rest of the sample. Rheumatoid factor was slightly more prevalent among individuals with peripheral joint fusion.

Seropositivity was significantly greater among individuals with any of the above-named radiologic alterations than in those without such findings. Examining specific (e.g., radiologic changes limited to the wrist) and combinations of diagnostic components

| Involvement (#)                           | RF positivity (p value) | CCP positivity (p value) |
|------------------------------------------|-------------------------|--------------------------|
| No inflammation-relatable radiologic alteration (48) | 7 Chi square = 30.6717 (< 0.0001) | 3 Chi square = 20.3910 (< 0.0001) |
| MCC/MTT (45)                             | 32 Chi square = 11.249 (< 0.001) | 21 Chi square = 0.153 (n.s.) |
| Subchondral erosion (57)                 | 41 Chi square = 13.670 (< 0.001) | 23 Chi square = 14.220 (< 0.001) |
| Peripheral joint fusion (30)             | 20 Chi square = 4.350 (< 0.03) | 12 Chi square = 1.029 (n.s.) |
| Arthritis mutilans (8)                    | 6 Fisher exact = 0.124 (n.s.) | 6 Fisher exact = 0.208 (n.s.) |
| Marginal erosions (22)                    | 12 Chi square = 0.334 (n.s.) | 8 Chi square = 1.9429 (n.s.) |
| Erosions only wrists (20)                 | 16 Chi square = 141.5391 (< 0.00001) | 9 Chi square = 72.4142 (< 0.00001) |
| Subchondral erosions + Fusion + MCC/MTT (9) | 9 Fisher exact (< 0.00001) | 7 Fisher exact (< 0.00001) |
| Fusion + MCC/MTT (7)                      | 5 Fisher exact (< 0.00001) | 3 Fisher exact (< 0.00001) |
| Subchondral erosions + Fusion             | 8 Chi square = 101.9613 (< 0.00001) | 5 Chi square = 58.1568 (< 0.00001) |
(Table 2 and Table 3) revealed these findings to be significantly more likely to have positive serologies.

The association of these findings with greater seropositivity suggests that these derive from a different process than producing marginal erosions. Radiologic recognition is critical and perhaps more pertinent to patient care than diagnoses based on serologies. Although radiologic alterations have major implications in clinical decision making related to the aggressiveness of therapeutic intervention [36], there is an additional consideration: Occupational therapy efforts are essential to prevent/reduce loss of range of motion in individuals with spondyloarthropathy, in contrast to RA, in which primary efforts are directed to physical therapy intervention to prevent/reduce deformities.

These findings indicate that the correlation between serological tests and modes of radiological damage is weak. Previous studies have shown biomechanical differences between radiological manifestations leading to subchondral erosions and joint fusion compared to marginal erosions [37,38]. Given these findings, investigation (e.g., using cytokine or proteomic parameters or biopsies) into the underlying pathophysiologic processes causing radiological damage in RA should segregate individuals not only according to serological findings, but also according to specific radiological signs.

Prospectively, a multidimensional approach, taking articular as well as extraarticular phenomena into account, could enable a deeper understanding of the inflammation process - or processes - associated with chronic peripheral arthritis. This could lead to a reassessment of the current classification paradigm, in which radiology and radiographic findings are viewed independently, and which arguably does not do justice to the complexity of the disease. A more differentiated classification system might lead to a therapeutic approach in which serological and radiographic findings are all taken into account, and therapy is tailored for the specific findings of the individual patient.

References
1. Pratt AG, Isaacs JD (2014) Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol 28: 651-659.
2. Kaneko Y, Kuwana M, Kameda H, Takeuchi T (2011) Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 50: 1268-1274.
3. Rothschild BM (2013) What qualifies as rheumatoid arthritis? World J of Rheumatol 3: 3-5.
4. Rothschild BM, Martin LD (2006) Skeletal Impact of Disease. (33rd edn), Albuquerque: New Mexico Mus Natural Hist Press, Mexico.
5. Rothschild BM, Woods RJ, Ortel W (1990) Rheumatoid arthritis “In the buff”: Erosive arthritis in representative defleshed bones. Am J Phys Anthropol 82: 441-449.
6. Francois RJ, Eulderink F, Bywaters EG (1995) Commented glossary for rheumatic spinal diseases, based on pathology. Ann Rheum Dis 54: 615-625.
7. Hacking P, Allen T, Rogers J (1994) Rheumatoid arthritis in a medieval skeleton. Intl J Osteoarcheol 4: 251-255.
8. Rogers J, Waldron T, Dieppe P, Watt I (1987) Arthropathies in palaeopathology: The basis of classification according to most probable cause. J Archaeol Science 14: 179-193.
9. Rothschild BM (1997) Two faces of "rheumatoid arthritis": Type A versus type B disease. J Clin Rheumatol 3: 334-338.
10. Rothschild BM, Woods RJ (1991) Spondyloarthropathy: Erosive arthritis in representative defleshed bones. Amer J Phys Anthropol 85: 125-134.
11. Rothschild BM, Woods RJ, Rothschild C (1992) Calcium pyrophosphate deposition disease: Description in defleshed skeletons. Clin Exp Rheumatol 10: 557-564.
12. Rothschild BM, Heathcote GM (1995) Characterization of gout in a skeletal population sample: Presumptive diagnosis in a Micronesian population. Am J Phys Anthropol 98: 519-525.
13. Rothschild BM, Woods RJ, Rothschild C, Sebes JI (1992) Geographic distribution of rheumatoid arthritis in ancient North America: Implications for pathogenesis. Semin Arthritis Rheum 22: 181-187.
14. Rothschild BM, Pingitore C, Eaton M (1998) Dactylitis: Implications for clinical practice. Semin Arthritis Rheum 28: 41-47.
15. Silman AJ (1997) Problems complicating the genetic epidemiology of rheumatoid arthritis. J Rheumatol 24: 194-196.
16. Ingegnol F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: Clinical applications. Dis Markers 35: 727-734.
17. Litwin SD, Singer JM (1965) Studies of the incidence and significance of anti-gamma globulin factors in the aging. Arthritis Rheum 8: 538-550.
18. Nisihara R, Kubis MM, Rodrigues PC, Skare T, Mocelin V, et al. (2013) Antinuclear antibodies and rheumatoid factor positivity in healthy elderly adults: A cross-sectional study in 336 individuals. J Am Geriatr Soc 61: 2044-2046.
19. Gadeholt O (2017) Rheumatoid arthritis is not a single disease. Clin Exp Rheumatol: Suppl 104: 20-21.
20. Gadeholt O, Feuchtenberger M, Wech T, Schwanec EC (2019) Power-dopler perfusion phenotype in RA patients is dependent on anti-citrullinated peptide antibody status, not on rheumatoid factor. Rheumatol Intl 39: 1019-1025.
21. Gottenberg JE, Couvouzis DS, Hernandez MV, Iannone F, Lie E, et al. (2016) A brief report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: Results from the pan-european registry analysis. Arthritis Rheumatol 68: 1346-1352.
22. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, et al. (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: A meta-analysis. Ann Rheum Dis 72: 329-336.
23. Quinn MA, Green MJ, Marzo-Ortega H, Praudman S, Karim Z, et al. (2003) Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 48: 3039-3045.
32. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) Rheumatoid arthritis classification criteria: An american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581.

33. Komsalova LY, Martinez Salinas MP, Jiménez JF (2020) Predictive values of inflammatory back pain, positive HLA B27 antigen and acute and chronic magnetic resonance changes in early diagnosis of spondyloarthritis. A study of 133 patients. PLoS One 15: e0244184.

34. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van ’t Hof MA, et al. (1992) Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 35: 26-34.

35. Resnick D (2003) Diagnosis of Bone and Joint Disorders. (4th edn), WB Saunders, Philadelphia.

36. Lin Y-J, Anzaghe M, Schulke S (2020) Update on the Pathomechanism, diagnosis and treatment options for rheumatoid arthritis. Cells 9: 880.

37. Reddy NP, Rothschild BM, Verrall E, Joshi A (2001) Noninvasive measurement of acceleration at the knee joint in patients with rheumatoid arthritis and spondyloarthropathy of the knee. Ann Biomed Engineer 29: 1106-1111.

38. Shah EN, Reddy N, Rothschild BM (2005) Fractal analysis of acceleration signals from patients with CPPD, rheumatoid arthritis, and spondyloarthropathy of the finger joint. Comput Methods Programs Biomed 77: 233-239.